Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection

Corrado P. Marini, MD, FACS,a Erin Lewis, MD, MPH,a Patrizio Petrone, MD, PhD, MPH, MHSA, FACS,b Ariela Zenilman, MD,a Zhai Lu, BS,a Aksim Rivera, MD,a and John McNelis, MD, FACS, FCCM,a b Bronx and Mineola, NY

ABSTRACT
Background: Deep vein thrombosis (DVT) has been reported to occur at different rates in patients with coronavirus disease 2019 (COVID-19). Limited data exist regarding comparisons with non—COVID-19 patients with similar characteristics. Our objective was to compare the rates of DVT in patients with and without COVID-19 and to determine the effect of DVT on the outcomes.

Methods: We performed a retrospective, observational cohort study at a single-institution, level 1 trauma center comparing patients with and without COVID-19. The 573 non—COVID-19 patients (age, 61 ± 17 years; 44.9% male) had been treated from March 20, 2019 to June 30, 2019, and the 213 COVID-19 patients (age, 61 ± 16 years; 61.0% male) had been treated during the same interval in 2020. Standard prophylactic anticoagulation therapy consisted of 5000 U of heparin three times daily for the medical patients without COVID-19 who were not in the intensive care unit (ICU). The ICU, surgical, and trauma patients without COVID-19 had received 40 mg of enoxaparin daily (not adjusted to weight). The patients with COVID-19 had also received enoxaparin 40 mg daily (also not adjusted to weight), regardless of whether treated in the ICU. The two primary outcomes were the rate of deep vein thrombosis (DVT) in the COVID-19 group vs that in the historic control and the effect of DVT on mortality. The subgroup analyses included patients with adult respiratory distress syndrome (ARDS), pulmonary embolism (PE), and intensive care unit patients (ICU).

Results: The rate of DVT and PE for the non—COVID-19 patients was 12.4% (71 of 573) and 3.3% (19 of 573) compared with 33.8% (72 of 213) and 7.0% (15 of 213) for the COVID-19 patients, respectively. Unprovoked PE had developed in 10 of 15 COVID-19 patients (66.7%) compared with 8 of 497 non—COVID-19 patients (1.6%). The 60 COVID-19 patients with ARDS had an incidence of DVT of 46.7% (n = 28). In contrast, the incidence of DVT for the 153 non—COVID-19 patients with ARDS was 28.8% (n = 44; P = .01). The COVID-19 patients requiring the ICU had had an increased rate of DVT (39 of 90; 43.3%) compared with the non—COVID-19 patients (33 of 123; 33.3%; P = .01). The risk factors for mortality included age, DVT, multiple organ failure syndrome, and prolonged ventilatory support with the following odd ratios: 1.030 (95% confidence interval [CI], 1.002—1.058), 2.847 (95% CI, 1.356—5.5979), 4.438 (95% CI, 1.973—9.985), and 5.321 (95% CI, 1.973—14.082), respectively.

Conclusions: The incidence of DVT for COVID-19 patients receiving standard-dose prophylactic anticoagulation that was not weight adjusted was high, especially for ICU patients. DVT is one of the factors contributing to increased mortality. These results suggest a reevaluation is necessary of the present standard-dose thromboprophylaxis for patients with COVID-19. (J Vasc Surg Venous Lymphat Disord 2022;10:803—10.)

Keywords: COVID-19; Deep vein thrombosis; Infection; Outcome
VTE of 21%, with a rate of 5% for patients not in the intensive care unit (ICU) and 31% for ICU patients, with the odds of mortality increasing by as much as 74% with VTE. Because of the various rates of DVT reported by previous studies, the association of elevated D-dimer levels with an increasing severity of COVID-19, and the extent to which the development of DVT in patients with COVID-19 can increase mortality, we designed the present study to investigate the rate of DVT, relationship of D-dimer levels with DVT, and disease severity and their effects (ie, DVT, D-dimer levels) on mortality by comparing COVID-19 patients to a historical cohort without COVID-19.

METHODS

The institutional review board approved the present retrospective record review and waived the requirement for written informed consent. The present study included 786 patients divided into two groups: 213 COVID-19 patients who had been admitted from March 20 to June 30, 2020 and 573 non—COVID-19 patients who had been admitted from March 20 to June 30, 2019. All the patients had undergone screening for DVT using duplex ultrasound (US). Because of our medical center’s logistic changes resulting from the need to admit COVID-19 patients, all elective medical and surgical admissions had been cancelled starting in March 2020. Therefore, the cohort group of non—COVID-19 patients could not be concurrent, because the vast majority of hospital beds were reserved for COVID-19 patients. The data acquired included demographics, diagnosis, service admission, admission to the ward or ICU, laboratory data (including prothrombin time, international normalized ratio, activated partial thromboplastin time, and D-dimer levels on admission [DD-Adm] and at compression US [DD-CUS]), DVT prophylaxis, the presence of COVID-19 pneumonia (PNA), ARDS (defined by the Berlin criteria), the need for mechanical ventilation (MV), the occurrence of DVT, multiple organ failure syndrome (MOFS), PE, and mortality. Critical PNA (Crit-PNA) was defined by the presence of >50% lung infiltrates on the computed tomography (CT) scan of the chest of patients with arterial oxygen saturation <90% on room air with an arterial partial pressure of oxygen/fraction of inspired oxygen ratio of <300 breathing at a respiratory rate >30 breaths/min. PE was identified using CT pulmonary angiography (CTPA) in both groups. Patients with a diagnosis of PE underwent CTPA according to the presence of symptoms (sinus tachycardia, unexplained hypotension, worsening respiratory status). The medical patients who were not in the ICU and did not have COVID-19 had received subcutaneously administered unfractionated heparin 5000 U 3 times daily for thromboprophylaxis. The medical ICU, surgical, and trauma patients had received enoxaparin at a dose of 40 mg once daily (not adjusted to body weight). All COVID-19 patients, both ICU and non-ICU, had received enoxaparin at 40 mg once daily.

The regimen did not change during the study period. Patients with DVT were treated with enoxaparin at 1 mg/kg/day every 12 hours. All the COVID-19 patients had undergone weekly DVT surveillance. In contrast, the 573 patients without COVID-19 had undergone duplex US scans according to the presence of symptoms and clinical risk factors for VTE.

Statistical analysis. Continuous variables are reported as the mean ± standard deviation and were analyzed using an unpaired t test. The parametric data are presented as the median and interquartile range (IQR). Categorical variables were analyzed using the χ². The variables that were predictive of the outcome are reported as odds ratios (ORs) with 95% confidence intervals (CIs) and were identified with stepwise logistic regression analysis. The strength of the association between the categorical and scale variables was determined using the eta (η) coefficient test. The subgroup analyses included patients admitted to the ICU and stratified by DVT, ARDS, and PE. Statistical significance was accepted to correspond to a P value < .05.

RESULTS

Of the 3934 non—COVID-19 patients admitted from March 20 to June 30, 2019, 603 (15.3%) had undergone US for DVT in accordance with the clinical criteria and risk factors. Of these 603 patients, 456 had been admitted to medicine, 69 to general surgery, and 78 to the trauma service. A total of 34 patients, 30 in the non—COVID-19 group and 4 in the COVID-19 group, were removed from the analysis because they had developed chronic DVT, leaving 573 patients without COVID-19 (age, 61 ± 17 years; 257 men [44.9%]) for comparison with the 213 COVID-19 patients (age, 61 ± 16 years; 130 men [61.0%]), who had undergone weekly DVT surveillance. The comparison of the 573 non—COVID-19 patients with the 213 COVID-19 patients is presented in Table I.
Although no differences were found in patient age, more male patients and a greater incidence of diabetes mellitus, hypertension, smoking, and a body mass index >30 kg/m² were found in the COVID-19 group. Most of the 456 non–COVID-19 medical patients had undergone duplex CUS for leg pain, leg tenderness and/or swelling, and documentation of the source of PE. The non–COVID-19 surgical (n = 69) and trauma (n = 78) patients had undergone scanning for clinical symptoms. The incidence of DVT was 12.4% (71 of 573) in the non–COVID-19 patients compared with 33.8% (72 of 213) in the COVID-19 group (P = .0001). The incidence of PE doubled as a result of COVID-19: 3.3% (19 of 573) for the non–COVID-19 patients vs 7.0% (15 of 213) for the COVID-19 patients (P = .02). More patients in the COVID-19 group had developed unprovoked PE: 10 of 141 (7.0%) vs 8 of 502 (1.6%) in the non–COVID-19 group (P = .0006). The patients with unprovoked PE were younger than were those whose PE could be linked to DVT: 49 ± 11 years and 62 ± 10 years, respectively. However, other than age, no other difference was found—including mortality—between the 10 with unprovoked and 5 with DVT-related PE (Table II).

No difference was found in the mortality of patients with and without PE: 3 of 15 (20.0%) vs 47 of 198 (23.7%), respectively. In the COVID-19 group, the median DD-Adm was 1.50 μg/mL (IQR, 0.51-6.54 μg/mL), and the median DD-CUS was 2.26 μg/mL (IQR, 0.84-5.13 μg/mL; P = .29). A subgroup analysis of the 72 COVID-19 patients with DVT showed a nonsignificant difference between the DD-Adm and DD-CUS; median, 1.63 μg/mL (IQR, 0.48-7.41 μg/mL) and median, 3.49 μg/mL (IQR, 1.90-8.82 μg/mL), respectively (P = .58). The mean change between the DD-Adm and DD-CUS was 0.40 μg/mL (range, −0.71 to 2.89), indicating increases and decreases in the level of DD-Adm to CUS. In 42 patients, the DD-CUS was greater than the DD-Adm. In contrast, in 32 patients, the opposite had occurred. The patients with DVT-related PE had had greater levels of DD-CUS compared with those with unprovoked PE (median, 9.75 μg/mL; IQR, 5.41-31.25 μg/mL; vs median, 2.55 μg/mL; IQR, 1.32-5.24 μg/mL). The difference, however, did not achieve statistical significance. The median DD-CUS for the 198 patients without PE was 1.48 μg/mL (IQR, 0.51-5.84 μg/mL) and was 5.10 μg/mL (IQR, 1.53-6.38 μg/mL) for the 15 patients with PE (P = .47).

In contrast to the COVID-19 group, the 19 cases of PE in the non–COVID-19 patients were more frequently associated with DVT. Eight cases of PE had occurred in 502 patients without DVT (1.6%) vs 11 cases of PE in the 71 patients with DVT (15.5%). The mortality of the COVID-19 patients was 23.5% vs 4.0% (23 of 573) for the non–COVID-19 group. Of the deaths in the non–COVID-19 group, 18 had occurred in the medicine, 4 in the trauma, and 1 in the general surgery service. Patients with DVT had greater mortality in both groups: 16 of 502 without DVT (3.2%) and 7 of 71 with DVT (9.9%) in the non–COVID-19 group and 21 of 141 without DVT (14.9%) and 29 of 72 patients with DVT (40.3%) in the COVID-19 group.

### Analysis of COVID-19 patients stratified by outcome

Of the 213 patients with COVID-19, 50 (23.5%) had died of COVID-19 complications. The 50 patients who died...
Table II. Subgroup analyses of COVID-19 patients stratified by ARDS, DVT, PE, and ICU

| Variable | Total | With | Without | P value |
|----------|-------|------|---------|---------|
| **ARDS** | 213   | ARDS (n = 60) | No ARDS (n = 153) |         |
| Age, years | 61 ± 16 | 56 ± 14 | 63 ± 17 | .005    |
| Male sex | 130 (61) | 42 (70) | 88 (57.5) | .11     |
| DVT      | 72 (33.8) | 28 (46.7) | 44 (28.8) | .01     |
| DD-Adm, µg/mL | 1.50 (0.51-6.54) | 0.96 (0.46-3.46) | 2.70 (0.55-7.27) | .5      |
| DD-CUS, µg/mL | 2.26 (0.83-5.12) | 2.05 (0.66-5.12) | 2.37 (1.07-4.92) | .5      |
| PE       | 15 (7) | 2 (3.3) | 13 (8.5) | .24     |
| COVID-PNA | 89 (41.7) | 8 (13.3) | 81 (52.9) | .0001   |
| Crit-PNA | 90 (43.2) | 56 (93.3) | 34 (22.2) | .0001   |
| MOFS     | 96 (45) | 41 (88.3) | 55 (35.9) | .0001   |
| MV       | 86 (40.4) | 54 (90) | 32 (20.9) | .0001   |
| Mortality | 50 (23.4) | 21 (35) | 29 (18.9) | .0001   |
| **PE**   | 15 | PE (n = 5) | No PE (n = 10) |         |
| Age, years | 52 ± 15 | 62 ± 10 | 49 ± 11 | .04     |
| Male sex | 13 (86.7) | 3 (60) | 10 (100) | .09     |
| DD-Adm, µg/mL | 6.62 (5.41-13.26) | 5.51 (1.89-8.46) | 2.55 (1.32-5.24) | .5      |
| DD-CUS, µg/mL | 5.15 (1.88-8.46) | 5.00 (5.41-13.26) | 2.54 (1.32-5.24) | .01     |
| COVID-PNA | 7 (46.7) | 4 (80) | 3 (50) | .11     |
| Critical-PNA | 5 (33.3) | 1 (20) | 4 (40) | .60     |
| MOFS     | 3 (20) | 1 (20) | 2 (20) | 1.00    |
| MV       | 5 (33.3) | 1 (20) | 4 (40) | .60     |
| Mortality | 3 (20) | 1 (20) | 2 (20) | 1.00    |
| **DVT**  | 213 | DVT (n = 72) | No DVT (n = 141) |         |
| Age, years | 61 ± 16 | 60 ± 14 | 60 ± 17 | 1.00    |
| Male sex | 130 (61) | 49 (68) | 81 (57.4) | .14     |
| DD-Adm, µg/mL | 1.50 (0.51-6.54) | 1.63 (0.48-7.41) | 1.51 (0.54-4.15) | .49     |
| DD-CUS, µg/mL | 2.26 (0.83-5.12) | 3.49 (1.90-8.82) | 1.41 (0.63-3.49) | .01     |
| COVID-PNA | 89 (41.7) | 32 (44.4) | 57 (40.4) | .65     |
| PE       | 15 (7) | 5 (6.9) | 10 (7) | 1.00    |
| Critical-PNA | 90 (43.2) | 40 (55.6) | 50 (35.5) | .01     |
| MOFS     | 96 (45) | 41 (56.9) | 55 (39) | .01     |
| MV       | 86 (40.4) | 39 (40.2) | 47 (33.3) | .004    |
| Mortality | 50 (23.4) | 29 (40.3) | 21 (14.9) | .02     |
| **ICU**  | 213 | ICU (n = 90) | No ICU (n = 123) |         |
| Age, years | 61 ± 16 | 58 ± 14 | 64 ± 17 | 1.00    |
| Male sex | 130 (61) | 56 (64.4) | 72 (56.7) | .14     |
| DD-Adm, µg/mL | 1.50 (0.51-6.54) | 2.77 (0.63-7.58) | 1.15 (0.50-4.31) | .03     |
| DD-CUS, µg/mL | 2.26 (0.84-5.13) | 2.45 (1.13-5.15) | 1.85 (0.64-4.78) | .01     |
| DVT      | 72 (33.8) | 30 (43.3) | 33 (26) | .013    |
| PE       | 15 (7) | 5 (5.6) | 10 (7.9) | 1.00    |
| COVID-PNA | 89 (41.7) | 32 (35.6) | 57 (40.4) | .65     |
| Crit-PNA | 90 (43.2) | 50 (88.9) | 10 (7.0) | .01     |
| MV       | 86 (40.4) | 86 (95.6) | 0 (0.0) | .004    |
| Mortality | 50 (23.5) | 50 (55.6) | 0 (0.0) | .001    |

ARDS: Acute respiratory distress syndrome; COVID-19: coronavirus disease 2019; COVID-PNA: coronavirus disease 2019-associated pneumonia; Crit-PNA: critical pneumonia; DD-Adm: D-dimer level at admission; DD-CUS: D-dimer level at compression ultrasound. DVT: deep vein thrombosis. ICU: intensive care unit. MOFS: multiple organ failure syndrome. MV: mechanical ventilation. PE: pulmonary embolism.

Data presented as mean ± standard deviation, number (%), or median (interquartile range).
had had higher DD-Adm and DD-CUS levels and a greater incidence of DVT (58.0% vs 26.4%). Additionally, the nonsurvivors had had a greater incidence of Crit-PNA, ARDS, MOFS, and progression from Crit-PNA to ARDS. The mortality had increased from 12.9% (13 of 101) to 25.9% (15 of 58), 37.0% (10 of 27), and 44.4% (12 of 27) with a DD-CUS level of 0 to 1.99, 2.0 to 4.99, 5.0 to 10.0, and >10.0 µg/mL, respectively. The median level of DD-CUS for the survivors was lower (median, 1.7 µg/mL; IQR, 0.7-3.7 µg/mL) than that for the nonsurvivors (median, 4.4 µg/mL; IQR, 2.0-7.8 µg/mL). However, the higher DD-Adm and DD-CUS levels were not predictive of mortality on multivariable analysis. The variables predictive of mortality included increasing age (OR, 1.030; 95% CI, 1.002-1.058), DVT (OR, 2.847; 95% CI, 1.356-5.597), MOFS (OR, 4.438; 95% CI, 1.973-9.985), and MV (OR, 5.321; 95% CI, 1.973-14.082) (Table III).

### Table III. Analysis of COVID-19 patients stratified by outcome

| Variable          | Total (n = 213) | Alive (n = 163) | Dead (n = 50) |
|-------------------|----------------|----------------|--------------|
| Age, years        | 61 ± 17        | 60 ± 16        | 63 ± 19      |
| Sex               |                |                |              |
| Male              | 130            | 95             | 35           |
| Female            | 83             | 68             | 15           |
| DVT               | 72 (33.8)      | 43 (26.4)      | 29 (58)³     |
| PE                | 15 (7)         | 12 (7.4)       | 3 (6)        |
| Crit-PNA          | 90 (42.3)      | 54 (33.1)      | 36 (72)²     |
| ARDS              | 60 (28.2)      | 39 (23.9)      | 21 (42)²     |
| MOFS              | 96 (45)        | 57 (34.9)      | 39 (78)²     |
| DD-Adm, µg/mL     | 1.50 (0.51-6.54) | 1.39 (0.53-6.39) | 2.16 (0.51-12.7) |
| DD-CUS, µg/mL     | 2.26 (0.84-5.13) | 1.72 (0.66-3.65) | 4.37 (1.97-7.85)² |
| Progress to ARDS  | 56/90 (62.2)   | 18 (11)        | 38 (76)      |

*ARDs: Acute respiratory distress syndrome. COVID-19: coronavirus disease 2019. Crit-PNA: critical pneumonia. DD-Adm: D-dimer level at admission. DD-CUS: D-dimer level at compression ultrasound. DVT: deep vein thrombosis. MOFS: multiple organ failure syndrome. PE: pulmonary embolism.

Data presented as mean ± standard deviation, number, number (%), or median (interquartile range).

*P < .05.

### DISCUSSION

The cardinal feature of COVID-19 disease has been the respiratory compromise from the involvement of the
Table IV. Subgroup analysis of patients admitted to the ICU

| Variable    | ICU group (n = 131) | COVID-19 (n = 90) | Non–COVID-19 (n = 41) | P value |
|-------------|---------------------|-------------------|----------------------|---------|
| Age, years  | 61 ± 16             | 58 ± 14           | 50 ± 18              | 1.00    |
| Male sex    | 84 (64.1)           | 58 (64.4)         | 26 (63.4)            | .14     |
| DVT         | 42 (35)             | 39 (43.3)         | 3 (7.3)              | .001    |
| PE          | 5 (5.8)             | 5 (5.6)           | 0 (0.0)              | 1.00    |
| MV          | 125 (95.4)          | 86 (95.6)         | 39 (95.1)            | 1.00    |
| Mortality   | 59 (45)             | 50 (55.6)         | 9 (21.9)             | .01     |

COVID-19. Coronavirus disease 2019. DVT, deep vein thrombosis. ICU, intensive care unit. MV, mechanical ventilation. PE, pulmonary embolism. Data presented as mean ± standard deviation or number (%).

pulmonary endothelium, with the resulting two time-dependent phenotypes of COVID-19 pneumonia as described byGattinoni et al. Early studies had documented elevated circulating D-dimer levels associated with prothrombotic hypercoagulable states, reported to be as high as 20%, with a 25% rate of VTE, despite conventional pharmacologic prophylaxis. Two studies suggested that the D-dimer levels are associated with the severity of COVID-19 disease and mortality. Because of the various rates of DVT reported by previous studies, in the present study, we investigated the rate of DVT and the relationship between the D-dimer levels and DVT—in the context of disease severity—through comparisons of mortality between a COVID-19 cohort and a cohort without COVID-19. The rate of DVT in the COVID-19 group was 33.8%, despite conventional pharmacologic prophylaxis, which was greater than the 14.5% reported byBaccellieri et al. and the 20% reported by Malas et al. The rate of DVT in the 90 critically ill ICU patients was 43.3%, which was also higher than the rate of 27% of VTE reported by Klok et al. The relative rate of DVT for the patients with COVID-19 was 63.3% higher than the rate of DVT in the cohort of patients without COVID-19 admitted in 2019. Although some of the increased rate could be attributed to the weekly surveillance protocol implemented in the COVID-19 patients, the magnitude of the difference cannot be ascribed solely to the intensity of surveillance. Also, although the rate of DVT in the COVID-19 ICU patients was higher than that in the non-ICU patients (43.3% vs 26.8%, respectively), we observed a low incidence of DVT in the non–COVID-19 ICU patients (7.3% vs 12.8% for the patients in the ward). We believe that the lower rate of DVT in the non–COVID-19 ICU patients (compared with a mean rate of 12.7% of DVT in 1783 ICU patients reported in a meta-analysis of seven studies) might be—in part—the result of the small sample of ICU patients compared with the other studies. Additionally, the lower rate of DVT for the non–COVID-19 ICU patients was likely attributable to the increased compliance with effective DVT prophylaxis for these patients; effective DVT prophylaxis has been associated with a low incidence of VTE. Patients with DVT had a higher level of DD-CUS compared with the patients without DVT, without a considerable overlap in the peak D-dimer values, as documented by others. 

Furthermore, we failed to demonstrate a correlation between the D-dimer levels and the presence of either severe pneumonia and/or ARDS. Although a significant difference was found in the DD-CUS level between the survivors and nonsurvivors on univariate analysis, the significance was not retained after stepwise logistic regression analysis. Therefore, we could not corroborate the negative effects of elevated D-dimer levels on survival, as previously reported.

The incidence of PE in the COVID-19 cohort was 7.0%, consistent with the range of rates reported in previous studies. Ten of the 15 cases of PE (66.7%) were diagnosed in patients without DVT, consistent with the findings of Helms et al. The rate of unprovoked PE in the non–COVID-19 group was 1.6% (8 of 502 patients). Based on the high rate of DVT in our study, we believe that the prevalence of DVT in the COVID-19 group was not underestimated. We, therefore, propose that—at least in some cases—pulmonary thrombosis, rather than embolism, is the pulmonary pathologic entity associated with COVID-19. Other than a younger age for the patients with unprovoked PE, we could not document any differences, including the D-dimer level, that could help identify the risk factors for unprovoked PE. No difference was found in mortality between patients with unprovoked and DVT-related PE. All the cases of PE in the COVID-19 patients were not fatal. The mortality for 3 of 15 patients with PE was attributable to MOFS. In contrast to the reported higher ICU mortality in patients with PE, the mortality of the patients with PE was not greater than that
The 28.2% rate of ARDS was lower than the reported rate (range, 61%-81%) for patients requiring intensive care reported by other investigators.23,24 The rate of DVT for the patients with ARDS was almost double the rate of patients without ARDS (43.3% vs 28.8%), without a significant difference in the D-dimer levels. The higher rate of DVT in the patients with ARDS, despite chemoprophylaxis, could be, in part, explained by the presence of more risk factors for DVT in this group, including prolonged MV, protracted immobilization, and a longer length of ICU stay. We believe that—notwithstanding the previously stated risk factors—failure to monitor anti-factor Xa (anti-FXa) activity in patients receiving conventional, not weight-adjusted, enoxaparin prophylaxis was likely the main reason that patients with ARDS had a greater rate of DVT because it has been shown that patients requiring MV will fail to achieve adequate anti-FXa activity if they received a dose of enoxaparin similar to the dose administered to the patients in the ward.4 The 3.3% incidence of PE in this group was lower than the rate of 17% in a group of 92 patients with COVID-19 ARDS reported by Contou et al.22 Although others have shown that older age is associated with a greater risk of developing ARDS because of a potentially compromised immune response, the patients with ARDS in our study were younger than those without it. However, as reported by others, they had significantly higher mortality.25

Of the 90 patients with Crit-PNA, 56 (62.2%) experienced progression to ARDS. The progression to ARDS increased the fatality rate from 18.9% to 35.0%, confirming the findings of other investigators with respect to the rate of progression to ARDS from severe pneumonia and the associated increased fatality rate.26

The results of a retrospective study of 26 patients with severe COVID-19 in two French ICUs, 8 (31%) of whom had received conventional VTE prophylaxis and 18 (69%) had received therapeutic anticoagulation, suggested that early therapeutic anticoagulation might reduce the rate of VTE in ICU patients with severe COVID-19.27 The reduced rate of major thrombotic events and DVT in patients receiving therapeutic dose anticoagulation has been documented; however, it has not translated into a reduced rate of death for critically ill patients with COVID-19.28 Therapeutic anticoagulation with heparin for COVID-19 patients not requiring ICU level care has been shown to be superior to the usual care thromboprophylaxis from the standpoint of reducing the need for organ support and mortality, with a more limited benefit for thrombotic events (from 3.2% to 1.9%).29 In contrast, intermediate-dose prophylaxis of enoxaparin 1 mg/kg/d compared with standard-dose prophylaxis of 40 mg/d has been shown to be ineffective in reducing venous and arterial thrombosis in COVID-19 patients admitted to the ICU.30

Although our findings have corroborated the high incidence of VTE in COVID-19 patients, our study had many limitations, including its retrospective design and the comparison of a nonconcurrent group of patients who could not be properly matched. The non—COVID-19 patients had undergone symptom-driven DVT screening, with the possibility of missing asymptomatic events, and, thus, underestimating the incidence of DVT compared with the COVID-19 group who had undergone weekly surveillance. Because of the high proportion of obese patients in both groups, the absence of weight-adjusted dosing of enoxaparin prevented us from identifying whether conventional dosing might be the cause of some of the DVT prophylaxis failure. An additional limitation included the CTPA protocol without CT venography of the pelvis, limiting the evaluation of the iliac and pelvic veins not easily accessible for duplex CUS assessment, potentially overestimating the rate of unprovoked PE by failing to detect iliac and pelvic veins thrombosis, especially in patients who had received femoral vein catheters.

CONCLUSIONS

Based on our results, we have concluded that—despite conventional DVT prophylaxis—patients with COVID-19 will have a greater incidence of DVT and unprovoked PE compared with patients without COVID-19. The incidence of DVT was increased in patients requiring ICU care and MV despite conventional DVT prophylaxis with either subcutaneous administered heparin (5000 U three times daily) or nonweight-adjusted enoxaparin 40 mg once or twice daily. We believe that although the development of DVT increases the risk of mortality, it is unclear whether DVT contributes directly to mortality or is a marker of more severe disease. Because the course of COVID-19 is characterized by a progression from the asymptomatic incubation period (days 1-5) to symptomatic (days 6-11) to the early and late pulmonary phases (days 11-14 and 14 to >30 days), it is likely that effectiveness of thromboprophylaxis or full anticoagulation depends on the timing and dose of its administration in relation to the symptoms and severity of the disease associated with the course of COVID-19.31 The following questions could not be answered by our study. In view of the high incidence of DVT in COVID-19 patients, the question remains whether—despite the conventional prophylaxis with either unfractionated heparin or enoxaparin—non-ICU patients with rapidly increasing D-dimer levels after admission and no contraindications should receive a higher prophylactic dose of low-molecular-weight heparin such as enoxaparin 0.5 mg/kg twice daily or 1 mg/kg once daily instead of the conventional dose. Another question is whether weight-adjusted low-molecular-weight heparin thromboprophylaxis with anti-FXa—guided dose adjustment to achieve target levels of anticoagulation would be more
appropriate. In addition, it is unknown whether the dosing should be different for COVID-19 patients in the ICU compared with COVID-19 patients not requiring the ICU according to the phase of pulmonary compromise, early vs late, and the D-dimer level. Additionally, it remains to be determined whether a relationship exists between the specific treatment a patient is receiving, such as antiviral vs anti-inflammatory and/or antimicrobial, and the effectiveness of the thromboprophylaxis or anticoagulation therapy. We believe that—pending the results from additional randomized clinical trials that address the potential effects of the timing and dose of thromboprophylaxis in relation to COVID-19 progression—a single-dose static approach might be inferior to one that tailors the dose to the specific phase of COVID-19 according to the timing and symptoms and, possibly, the D-dimer level.

AUTHOR CONTRIBUTIONS
Conception and design: CM, JM
Analysis and interpretation: CM, EL, PP, JM
Data collection: CM, AZ, ZL, AR
Writing the article: CM, EL, PP
Critical revision of the article: CM, EL, PP, AZ, ZL, AR, JM
Final approval of the article: CM, EL, PP, AZ, ZL, AR, JM
Statistical analysis: CM, EL
Obtained funding: Not applicable
Overall responsibility: PP

REFERENCES
1. The New York Times. Coronavirus in the U.S.: Latest Map and Case Count. Available at: https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html. Accessed April 13, 2021.
2. Hashim MJ, Alsuwaidi AR, Khan G. Population risk factors for COVID-19 mortality in 93 countries. J Epidemiol Glob Health 2020;10:204-8.
3. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489-500.
4. Rapkiewicz AV, Mai X, Carson SE, Pittaluga S, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClini-
cMedicine 2020;24:100434.
5. Suh YJ, Hong H, Ohana M, Bompard F, Revel MP, Valle C, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 2021;298:E70-80.
6. Malas MB, Naazie IN, Elayed N, Mathilouhi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine 2020;29:100639.
7. Ranieri VM, Rubenfeld GD, Thompson BT. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-33.
8. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020;46:1039-102.
9. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421-4.
10. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
11. Yu H-H, Qin C, Chen M, Wang W, Tian D-S. D-dimer level is associated with the severity of COVID-19. Thromb Res 2020;195:219-25.
12. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care 2020;8:49.
13. Baccellieri D, Bertoglio L, Apruzzi L, Ardita V, D’Angelo A, Bossi M, et al. Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak. Phlebology 2021;36:375-83.
14. Klok FA, Kruip MHA, van der Meer NJM, Arbous MS, Commers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7.
15. Malato A, Dentali F, Siragusa S, Fabbiano F, Kagoma Y, Boddi M, et al. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus 2015;13:559-68.
16. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-9.
17. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vatikis PT, Coldhaver SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
18. Madhavan MV, Gupta A, Bickel B. The relationship between D-dimer levels and deep venous thrombosis in COVID-19: an analysis from a quaternary academic medical center in New York City. Circulation 2020:99:613-6.
19. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: analysis of 483 cases. Diabetes Metab Syndr 2020;14:2245-9.
20. Sakr Y, Giovini M, Leone M, Pizzilli G, Kortgen A, Bauer M, et al. Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review. Ann Intensive Care 2020;10:124.
21. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089-98.
22. Contou D, Pajot O, Cally R, Logre E, Frasset M, Mentec H, et al. Pulmonary embolism or thrombosis in ARDS COVID-19 patients: a French monocenter retrospective study. PloS One 2020;15:e0238413.
23. Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS), clinical features and differences from typical pre-
COVID-19 ARDS. Med J Aust 2020;213:54-6.
24. Dutt S, Simcox D, Downey C, McNlenaghan D, King C, Gauran M, et al. Pulmonary thrombosis and/or anticoagulant use in COVID-19 patients: randomised placebo controlled trial. BMJ 2020;370:m47-6.
25. Delabranche X, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020;18:1743-6.
26. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19: a randomized controlled trial. JAMA Intern Med 2020;180:934-43.
27. N Engl J Med 2021;385:790-802.
28. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021;385:777-89.
29. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021;385:790-802.
30. INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracor-
poreal membrane oxygenation treatment, or mortality among pa-
Glob Health 2020;10:204-8.

Submitted Aug 6, 2021; accepted Oct 13, 2021.